Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Nalos

Cardiovascular Disease Bakersfield, CA Medical Doctor

NPI 1609055078 CMS profile 299166

2901 Sillect Ave, Suite 100, Bakersfield, CA 93308

Open in the dashboard

General payments

$9,611

333 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,845 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Peter Nalos of Bakersfield, CA is reported in the CMS Open Payments database as having received $9,611 across 333 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,845 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 81st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,341 35
2024 General $1,758 49
2023 General $1,473 47
2022 General $1,401 56
2021 General $878 38
2020 General $890 34
2019 General $1,870 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Nalos
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Peter Nalos were reported at $1,341. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Peter Nalos Cardiovascular Disease median Middle half National median
2019 $1,870 $450 $127–$1,392 $163
2020 $890 $242 $77–$751 $114
2021 $878 $335 $101–$1,037 $132
2022 $1,401 $395 $121–$1,211 $149
2023 $1,473 $443 $136–$1,283 $160
2024 $1,758 $450 $136–$1,323 $164
2025 $1,341 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,297 149 payments
  2. Medtronic Vascular, Inc. $1,130 37 payments
  3. Merck Sharp & Dohme Corporation $617 34 payments
  4. Amgen Inc. $610 34 payments
  5. Novartis Pharmaceuticals Corporation $328 16 payments
  6. AstraZeneca Pharmaceuticals LP $288 8 payments
  7. CVRx, Inc. $220 6 payments
  8. HeartFlow, Inc. $160 2 payments
  9. Pfizer Inc. $149 8 payments
  10. iRhythm Technologies, Inc. $83 4 payments
  11. Other $728 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,597 332 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. GALLANT Cardiac Rhythm Management $717 15 payments
  2. VERQUVO $703 38 payments
  3. GALLANT Cardiac Rhythm Management $645 15 payments
  4. Repatha $610 34 payments
  5. GALLANT Structural Heart $392 8 payments
  6. Fortify Assura, Ellipse ICD $360 11 payments
  7. Unify Assura CRT Defibrillator $313 10 payments
  8. Azure $263 9 payments
  9. LEQVIO $248 12 payments
  10. Barostim Neo System $220 6 payments
  11. Other $5,566 201 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

5,840

Median for Cardiology: 2,533

Drug cost

$628,529

Median for Cardiology: $485,213

Branded share of claims

22.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 356 $388,468
Xarelto Rivaroxaban Brand 98 $87,479
Entresto Sacubitril/Valsartan Brand 28 $29,797
Flecainide Acetate Generic 420 $16,638
Repatha Sureclick Evolocumab Brand 11 $10,496
Jardiance Empagliflozin Brand 13 $8,712
Farxiga Dapagliflozin Propanediol Brand 15 $8,039
Metoprolol Succinate Generic 454 $7,345
Sotalol Sotalol Hcl Brand 392 $6,945
Nebivolol Hcl Generic 134 $5,267

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$422,480

Of which drugs: $989

Medicare patients

1,250

Average age 76

Services billed

10,620

598 women, 652 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Atrial fibrillation 49%
Arthritis 48%
Diabetes 41%
Heart failure 36%
Chronic kidney disease 31%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 21 84 $814
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 15 1,501 $156
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 15 16 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $128
$128 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $87
$87 — —
VYNDAQEL
  • PFIZER INC. $73
$73 — —
Repatha
  • Amgen Inc. $62
$62 11 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record